| INTRODUCTION
Dementia is a major public health problem worldwide, partly due to the increasing life expectancy of the population. Epidemiological data for developed countries show that the prevalence of Alzheimer's disease (AD) in adults at age 60-64 is less than 1% in Europe, but after age 65, the incidence doubles every 5 years of life. 1, 2 Overall, neurological diseases that cause dementia are the third leading cause of life with disabilities globally. 3 The most common primary cause of dementia is AD, 4 which represents over 65% of all dementia cases, followed by vascular dementia (VaD), which is responsible for most of the remainder. 4 AD is characterized by an insidious onset with a slow progressive course with impairment of memory, language, and visuospatial functions ultimately resulting in global cognitive impairment. 5 VaD represents a large group of clinical entities associated with vascular changes 6 and heterogeneous clinical presentation described as less insidious in onset compared to AD, which shows a stepwise decline in cognitive abilities.
7
The most important feature of VaD is that it can be prevented by acting on risk factors, stressing the need for an early diagnosis of VaD. 
11
The use of sensitive and specific biomarkers such as tau proteins, especially phosphorylated tau proteins, could contribute to the earlier and more accurate diagnosis of both AD and VaD. 12 In this study, we analyzed cerebrospinal fluid (CSF) levels of total tau protein (t-tau) and tau protein phosphorylated at threonine 231 (p-tau 231 ) in patients with AD and VaD, as well as in healthy controls (HC), to assess the diagnostic accuracy of these biomarkers in the CSF in differentiation of AD from VaD and HC.
| PATIENTS AND METHODS

| Patients
Patients who met all inclusion criteria were invited to participate in the study. The patients were examined at two study site, General
Hospital Varaždin and Clinical Hospital Center Rebro Zagreb from
August 2011 until May 2015.
At the initial visit, the patients signed an informed consent form.
Consent form was explained in details to patients and caregiver.
Patient and caregiver gave consent to participate in the study as well as to perform lumbar puncture. The possible complications of the procedure were explained in detail. All procedures involving human subjects were performed with the approval of the Central 
| Cerebrospinal fluid (CSF) sampling and analysis
Lumbar puncture was performed between 8 am and 10 am, and CSF was obtained by a routine protocol from the L3/L4 or L4/L5 intervertebral space. After the first few drops were discharged, 2 mL of the CSF was collected in polypropylene tubes. In case of a traumatic puncture with hemorrhagic CSF, these samples were excluded from analysis. CSF samples were stored at 4°C, wrapped in aluminum foil, and transported on ice to the laboratory. Hercules, CA, USA). There were no significant differences in the levels of total tau and p-tau 231 between the samples from the two different hospitals (Zagreb and Varaždin).
| Statistical analysis
For comparison of demographic, clinical, and laboratory parameters, the nonparametric Kruskal-Wallis test was used. Due to the relatively small sample sizes and because it does not require assumption of normal distributions, the nonparametric Mann-Whitney U test was used for some comparisons between the groups, in addition to the t test.
Receiver operating characteristic (ROC) curve analysis was used to evaluate the diagnostic value of the parameters from the variables in the differentiation of the examined groups. Cut-off levels of both markers used in the study were derived from the ROC curve analysis, with the sum of sensitivity and specificity maximized. In addition, the specificity of both markers in differentiating the groups, with sensitivity set to 85%, was determined. Sensitivity and specificity were visualized with confidence interval (CI) of 95%. In addition, the area under the ROC curve (AUC) was shown as an accuracy indicator. The correlation between CSF biomarkers was tested using the Spearman test 
| RESULTS
The demographic data of the subjects included in the study, their MMSE scores, and CSF levels of t-tau and p-tau 231 are shown in Table 1 . On average, patients with AD (U = 635, Z = −3.437, P = 0.001) and VaD patients (U = 132, Z = −2.484, P = 0.013) were significantly older than HC. However, because there was no significant correlation between age and CSF biomarker levels, the lower mean age of the HC (Table 3) . shows 90% sensitivity in differentiating subjects with AD vs HC, but the specificity of this group is less than 75%. Similarly, p-tau 231 differentiates subjects for VaD vs HC with sensitivity 80% and specificity 77.8%, and FS(p-tau 231 and MMSE) shows sensitivity 80% and specificity 85%, which makes it an ideal candidate biomarker.
| DISCUSSION
Vandermeeren and colleagues reported that t-tau was increased in patients with AD compared to HC, as confirmed by later studies.
14,15
Levels of t-tau were shown to be a marker of neural damage, increased not only in AD, but also in other primary causes of dementia. 16 In addition, subsequent investigations have confirmed that t-tau levels in CSF reflect the intensity of neuronal damage and degeneration. Therefore, t-tau levels can also be elevated in patients with vascular damage,
17
whereas the highest values of the t-tau protein have been described 
F I G U R E 3 Correlation between t-tau and p-tau 231 levels
in Creutzfeldt-Jakob's disease due to a very intensive neuronal degeneration. 18 In one study, the transient increase in CSF t-tau concentration in acute stroke positively correlated with the area of brain infarction, measured by computerized tomography. 17 Schönknecht et al 19 showed that t-tau levels were significantly higher in patients with AD compared to VaD, as well as HC and patients suffering from major depression. Several other authors confirmed these results, [20] [21] [22] although other authors reported divergent data. 23, 24 Some factors may explain these differences. According to several previous investigations, p-tau 231 is a marker highly specific of AD. [25] [26] [27] Thus, it can be detected very early in the CSF of patients with AD. 25 The p-tau 231 concentration alone has also shown a good correlation with the progression of the disease in a single patient with AD. 25, 26 Bürger and colleagues showed that ptau 231 levels were elevated in subjects with MCI and also inversely correlated with their MMSE score. 27 Also, the data from Hampel and collaborators agree with the notion that variations in p-tau 231 levels reflect differences in the degree of neuronal damage across AD patients. Although the strength of the correlations presently suggests no sufficient clinical utility to individual patients, p-tau 231 levels may be used to predict progression of brain atrophy in AD. 28 Hampel and collaborators demonstrated the discriminatory power of p-tau (p-tau 231 , p-tau 181 , p-tau 199 ) in differentiating patients with AD from HC as well as other types of dementia including VaD. 29 Unfortunately, due to insufficient number of patients with VaD, the discriminatory (cut-off) levels of p-tau 231 for VaD could not be demonstrated in that study. 29 A longitudinal study of CSF tau protein in AD and VaD showed a statistically significant difference in the concentrations of t-tau and ptau in AD (moderate to severe AD) compared to VaD, especially in the case of severe AD, but no significant differences in the levels of t-tau and p-tau 231 as MMSE scores after 6 months of monitoring compared to initial measurements. 30 It should be noted that our study revealed similar results, whereas our patients generally had milder dementia, as measured by MMSE scores, than the study of Wang and collaborators.
30
The present study took care to match subject groups as closely as possible for age, sex, and other demographic characteristics, so that confounding biases could be minimized. Nevertheless, HC were on average younger than subjects from the other groups, which could have influenced the outcome to some level. We also had a relatively fewer HC. The possible discrepancies could also result from differences in study design. To verify the reliability of our results, we therefore performed all CSF analyses with at least two internal sample controls.
Previous studies have shown that p-tau 231 CSF levels reliably differentiate patients with AD and HC. 31 Our results confirm and extend these observations, as they indicate that p-tau 231 CSF levels can also be used for differentiating subjects with VaD from HC. Additionally, in distinguishing between AD and VaD, we established that FS (p-tau 231
and MMSE) has a strong potential to offer earlier distinction between these conditions. This finding has not only clinical significance, but also potential to prevent development and complications of VaD at an early stage.
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